Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
Survey, Priorities, Activities, Participation
Brief summary
The purpose of this study is to distribute a questionnaire created for individuals living with chronic obstructive pulmonary disease (COPD) to assess their activities, participation, and healthcare and COPD-related research priorities. The data collected will be compared across diagnosed COPD stages and disease severity to determine the extent to which adults with COPD participate in the listed activities and identify their primary research and healthcare related priorities. The questionnaire was originally developed based on past research then verified by a panel of COPD and participation experts; as well as, individuals living with COPD in the form of focus groups. The questionnaire will now be administered to 200 individuals living COPD (50 in each GOLD stage) at three sites across Montreal where clinical data for each participant will be available. This phase will help establish the reliability of the questionnaire.
Interventions
OTHERPatient Survey
Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
Sponsors
AstraZeneca
McGill University
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of COPD * English or French speaking * Patient at one of the three participating sites with medical chart
Exclusion criteria
* No diagnosis of COPD by a healthcare professional * Unable to communicate in English or French * Unable to provide informed consent * No medical chart information at one of the three participating sites
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Prioritized Healthcare Topics | Baseline | Twenty-four healthcare topics were selected once again from a literature and expert panel review, as well as corroborated by individuals living with COPD in five focus groups. Example healthcare topics include: relief of breathlessness; increase maximal amount of exercise individuals living with COPD can do inside and outside their homes; and prevent-lung flare-ups. Participants were asked to indicate their preference of the topics by assigning a percentage of their time, in increments of 10%, to the various healthcare topics, for a total of 100% of their time. For the 24 healthcare topics, individuals could select up to 10 topics (10% times 10 topics, for 100% of their time). The top five topics are presented as the most important topics for the participants and are indicative of areas of focus for future healthcare and research. The top five were presented in accordance to the request from the working group who developed the survey and reviewed the results. |
| Number of Participants Who Prioritized Research Topics | Baseline | Individuals were asked to indicate their research priorities from a list of research topics using a modified willingness-to-pay method (Kawata et al., 2014). The willingness-to-pay method allows individuals to assign preference to various topics by assigning a percentage of funds to the topic. A list of 22 research topics (e.g., to relieve breathlessness in individuals living with COPD, to increase access to lung transplantations) was created for this study through a literature review, expert consultation, and five focus groups with individuals living with COPD (n=23, 27% women). Individuals were asked to assign a percentage of funds, in increments of 10% of funding, to the 22 COPD research topics. Participants could assign anywhere between 10% of funding to 100% of funding to the topics. The top five were presented in accordance to the request from the working group who developed the survey and reviewed the results. |
| Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Baseline | Participants will answer questions about their participation in 26 daily activities, as well as their desire to participate in each of the 26 daily activities. This is a measure of those who indicated they wanted to increase their participation. 10 of the 26 activities and their outcome measures are listed below. Activity 1: Walking from one place to another outside of your home on a flat surface. Activity 2: Moving from one place to another using motorized transportation. Activity 3: Climbing two or more flights of stairs. Activity 4: Walking up a hill. Activity 5: Participating in regular exercise. Activity 6: Walking from one place to another in your home. Activity 7: Carrying light objects on a flat surface. Activity 8: Carrying heavy objects on a flat surface. Activity 9: Carrying-out low intensity physical activities |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| COPD Assessment Test | Baseline | This questionnaire measure the impact COPD is having on well being and daily life. The CAT is an eight-item semantic differential scale from 0 to 5, where 0 is no impact and 5 is extremely impactful. Items include: I never cough\| I cough all the time, I have no phlegm (mucus) in my chest at all \| My chest is completely full of phlegm (mucus), My chest does not feel tight at all \| My chest feels very tight, When I walk up a hill or one flight of stairs, I am not breathless \| When I walk up a hill or one flight of stairs, I am very breathless, I am not limited doing any activities at home\| I am very limited doing activities at home, I am confident leaving my home despite my lung condition\| I am not at all confident leaving my home because of my lung condition, I sleep soundly \| I don't sleep soundly because of my lung condition, I have lots of energy I have no energy at all. Participants' scores were totaled and a score of ≥ 10 indicated higher than normal burden of disease. |
| Godin Leisure Time Physical Activity Questionnaire | Baseline | Self-reported physical activity levels measured in length of bouts over the previous 7 days to determine physical activity frequency. |
| Forced Expiratory Volume in 1-sec (FEV1) | Baseline | Individuals forced expiratory volume in 1-sec (FEV1) as assessed by spirometry |
| Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | baseline | An exacerbation was defined as a change in medication due to a COPD exacerbation (i.e., the prescription of prednisone or a medical action plan) as indicated in the medical chart or hospital admission due to a COPD exacerbation. |
| Satisfaction of Life Questionnaire | Baseline | This 5 item questionnaire was used to measure participants' level of life satisfaction. The higher the score, the higher the sense of life satisfaction. A score from 5-9 indicated extremely dissatisfied, 10-14 is dissatisfied, 15-19 indicated slightly below average life satisfaction. 20-24 is the average score, 25-29 is a high score indicative of higher life satisfaction and a score between 30-35 is a very high score and represent very high life satisfaction. |
| FEV1/FVC | Baseline | Individuals FEV1-to-forced vital capacity (FVC) ratio |
| Modified Medical Research Council Questionnaire on Breathlessness | Baseline | Self-reported intensity of activity related breathlessness as assessed by the modified Medical Research Council (mMRC) dyspnea scale (0-4). This questionnaire was used to measure participants' breathlessness burden using a single item scale from 0 to 4, where a score of 0-1 indicated mild breathlessness and 2-4 indicated increased breathlessness. |
Countries
Canada
Participant flow
Recruitment details
200 participants completed the AHRPQ. Of those, 52 were missing spirometry in medical records, 148 completed with spirometry for Quartile 1-4 analysis \[groups\], and 130 of the 148 completed spirometry, exacerbation and mMRC for Group A-D analysis.
Participants by arm
| Arm | Count |
|---|---|
| All Participants Participants answered an online survey and their medical chart information was gathered to compare responses across disease severity. This was a single arm study. | 200 |
| Total | 200 |
Baseline characteristics
| Characteristic | All Participants |
|---|---|
| Age, Continuous | 67.5 Years STANDARD_DEVIATION 8.8 |
| Asthma | 64 Participants |
| Cancer | 25 Participants |
| CAT (COPD assessment test) score ≥10 (higher than normal burden of disease ) | 163 Participants |
| CAT (COPD assessment test) score <10 (less than normal burden of disease) | 34 Participants |
| Cerebrovascular disease | 3 Participants |
| Chronic kidney disease | 5 Participants |
| Congestive heart failure | 15 Participants |
| Connective tissue disease | 3 Participants |
| Dementia | 1 Participants |
| Diabetes Mellitus | 18 Participants |
| Education Full-time/Part-time | 86 Participants |
| Education Unemployed/Retired/Disability | 108 Participants |
| Hemiplegia | 0 Participants |
| HIV/AIDS | 1 Participants |
| Household Income Above $60,000 | 43 Participants |
| Household Income Under $60,000 | 118 Participants |
| Liver disease | 4 Participants |
| Marital Status Married/Common Law | 108 Participants |
| Marital Status Single/Divorced/Widowed | 86 Participants |
| mMRC (Modified-Medical Research Council Questionnaire on breathlessness) 0-1 (mild breathlessnes) | 67 Participants |
| mMRC (Modified-Medical Research Council Questionnaire on breathlessness) ≥2 (increased breathlessness) | 129 Participants |
| Myocardial Infarction | 11 Participants |
| Peripheral vascular disease | 7 Participants |
| Pulmonary Rehab Attendance No | 112 Participants |
| Pulmonary Rehab Attendance Yes | 81 Participants |
| Race/Ethnicity, Customized Race Other | 12 Participants |
| Race/Ethnicity, Customized Race White | 181 Participants |
| Region of Enrollment Canada | 200 Participants |
| Sex: Female, Male Female | 96 Participants |
| Sex: Female, Male Male | 103 Participants |
| Smoking Ever smoked tobacco | 184 Participants |
| Smoking Never smoked tobacco | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 0 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
Primary
Number of Participants Who Prioritized Healthcare Topics
Twenty-four healthcare topics were selected once again from a literature and expert panel review, as well as corroborated by individuals living with COPD in five focus groups. Example healthcare topics include: relief of breathlessness; increase maximal amount of exercise individuals living with COPD can do inside and outside their homes; and prevent-lung flare-ups. Participants were asked to indicate their preference of the topics by assigning a percentage of their time, in increments of 10%, to the various healthcare topics, for a total of 100% of their time. For the 24 healthcare topics, individuals could select up to 10 topics (10% times 10 topics, for 100% of their time). The top five topics are presented as the most important topics for the participants and are indicative of areas of focus for future healthcare and research. The top five were presented in accordance to the request from the working group who developed the survey and reviewed the results.
Time frame: Baseline
Population: Participants answered an online survey and their medical chart information was gathered to compare responses across disease severity. Of the 148 participants, 130 completed the online survey with spirometry \& exacerbation and mMRC for Group ABCD analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Prioritized Healthcare Topics | Improve Your Ability to Improve Activities | 79 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Prioritized Healthcare Topics | Improve Physical Well-Being | 70 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Prioritized Healthcare Topics | Discuss COPD | 71 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Prioritized Healthcare Topics | Prevent Lung Flare-Ups | 74 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Prioritized Healthcare Topics | Relief of Breathlessness | 90 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Prioritized Healthcare Topics | Improve Your Ability to Improve Activities | 67 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Prioritized Healthcare Topics | Relief of Breathlessness | 79 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Prioritized Healthcare Topics | Improve Physical Well-Being | 62 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Prioritized Healthcare Topics | Discuss COPD | 61 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Prioritized Healthcare Topics | Prevent Lung Flare-Ups | 64 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Improve Physical Well-Being | 20 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Improve Your Ability to Improve Activities | 20 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Relief of Breathlessness | 23 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Discuss COPD | 18 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Prevent Lung Flare-Ups | 18 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Prevent Lung Flare-Ups | 18 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Improve Physical Well-Being | 15 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Discuss COPD | 19 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Improve Your Ability to Improve Activities | 22 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Relief of Breathlessness | 22 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Discuss COPD | 23 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Relief of Breathlessness | 21 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Improve Your Ability to Improve Activities | 15 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Prevent Lung Flare-Ups | 18 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Improve Physical Well-Being | 17 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Prevent Lung Flare-Ups | 20 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Discuss COPD | 11 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Improve Your Ability to Improve Activities | 22 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Relief of Breathlessness | 24 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Prioritized Healthcare Topics | Improve Physical Well-Being | 18 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Relief of Breathlessness | 11 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Prevent Lung Flare-Ups | 14 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Improve Your Ability to Improve Activities | 12 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Improve Physical Well-Being | 12 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Discuss COPD | 12 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Improve Your Ability to Improve Activities | 30 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Relief of Breathlessness | 36 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Improve Physical Well-Being | 26 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Prevent Lung Flare-Ups | 23 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Discuss COPD | 27 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Improve Your Ability to Improve Activities | 6 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Improve Physical Well-Being | 9 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Prevent Lung Flare-Ups | 7 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Relief of Breathlessness | 5 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Discuss COPD | 6 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Discuss COPD | 16 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Relief of Breathlessness | 27 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Prevent Lung Flare-Ups | 20 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Improve Your Ability to Improve Activities | 19 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Healthcare Topics | Improve Physical Well-Being | 15 participants |
Comparison: Improve your ability to perform activities in and out of your homep-value: 0.31Chi-squared
Comparison: Prevent lung flare-upsp-value: 0.96Chi-squared
Comparison: Discuss COPD and its progressionp-value: 0.04Chi-squared
Comparison: Improve your physical well-beingp-value: 0.7Chi-squared
Comparison: Relief of breathlessnessp-value: 0.91Chi-squared
Comparison: Relief of breathlessnessp-value: 0.01Chi-squared
Comparison: Improve your ability to perform activities in and out of your homep-value: 0.49Chi-squared
Comparison: Prevent lung flare-upsp-value: 0.93Chi-squared
Comparison: Discuss COPD and its progressionp-value: 0.6Chi-squared
Comparison: Improve your physical well-beingp-value: 0.31Chi-squared
Primary
Number of Participants Who Prioritized Research Topics
Individuals were asked to indicate their research priorities from a list of research topics using a modified willingness-to-pay method (Kawata et al., 2014). The willingness-to-pay method allows individuals to assign preference to various topics by assigning a percentage of funds to the topic. A list of 22 research topics (e.g., to relieve breathlessness in individuals living with COPD, to increase access to lung transplantations) was created for this study through a literature review, expert consultation, and five focus groups with individuals living with COPD (n=23, 27% women). Individuals were asked to assign a percentage of funds, in increments of 10% of funding, to the 22 COPD research topics. Participants could assign anywhere between 10% of funding to 100% of funding to the topics. The top five were presented in accordance to the request from the working group who developed the survey and reviewed the results.
Time frame: Baseline
Population: Participants answered an online survey and their medical chart information was gathered to compare responses across disease severity. Of the 148 participants, 130 completed the online survey with spirometry \& exacerbation and mMRC for Group ABCD analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Prioritized Research Topics | To prevent lung flare ups | 74 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Prioritized Research Topics | To improve maximal amount of exercise | 68 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Prioritized Research Topics | To relieve breathlessness in COPD | 113 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Prioritized Research Topics | To prevent the development of COPD | 85 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Prioritized Research Topics | To increase the ability to exercise | 70 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Prioritized Research Topics | To relieve breathlessness in COPD | 98 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Prioritized Research Topics | To prevent lung flare ups | 62 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Prioritized Research Topics | To increase the ability to exercise | 61 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Prioritized Research Topics | To improve maximal amount of exercise | 57 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Prioritized Research Topics | To prevent the development of COPD | 74 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To increase the ability to exercise | 20 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To relieve breathlessness in COPD | 28 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To prevent the development of COPD | 18 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To prevent lung flare ups | 18 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To improve maximal amount of exercise | 21 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To improve maximal amount of exercise | 12 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To prevent lung flare ups | 18 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To relieve breathlessness in COPD | 29 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To prevent the development of COPD | 26 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To increase the ability to exercise | 14 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To increase the ability to exercise | 17 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To improve maximal amount of exercise | 15 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To relieve breathlessness in COPD | 26 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To prevent the development of COPD | 22 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To prevent lung flare ups | 14 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To improve maximal amount of exercise | 20 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To prevent lung flare ups | 24 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To increase the ability to exercise | 19 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To relieve breathlessness in COPD | 30 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Prioritized Research Topics | To prevent the development of COPD | 19 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To improve maximal amount of exercise | 6 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To increase the ability to exercise | 11 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To relieve breathlessness in COPD | 20 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To prevent the development of COPD | 15 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To prevent lung flare ups | 14 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To improve maximal amount of exercise | 29 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To prevent the development of COPD | 30 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To prevent lung flare ups | 24 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To increase the ability to exercise | 29 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To relieve breathlessness in COPD | 40 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To increase the ability to exercise | 7 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To relieve breathlessness in COPD | 7 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To improve maximal amount of exercise | 4 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To prevent lung flare ups | 3 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To prevent the development of COPD | 9 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To relieve breathlessness in COPD | 31 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To prevent lung flare ups | 21 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To improve maximal amount of exercise | 18 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To increase the ability to exercise | 14 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Prioritized Research Topics | To prevent the development of COPD | 20 participants |
Comparison: To relieve breathlessness in adults living with COPDp-value: 0.73Chi-squared
Comparison: To prevent the development of COPDp-value: 0.23Chi-squared
Comparison: To prevent lung flare-ups in adults living with COPDp-value: 0.14Chi-squared
Comparison: To increase the ability of adults living with COPD to exercisep-value: 0.52Chi-squared
Comparison: To improve the maximal amount of exercise of adults living with COPD in and out of the homep-value: 0.11Chi-squared
Comparison: To relieve breathlessness in adults living with COPDp-value: 0.14Chi-squared
Comparison: To prevent the development of COPDp-value: 0.73Chi-squared
Comparison: To prevent lung flare-ups in adults living with COPDp-value: 0.2Chi-squared
Comparison: To increase the ability of adults living with COPD to exercisep-value: 0.17Chi-squared
Comparison: To improve the maximal amount of exercise of adults living with COPD in and out of the homep-value: 0.02Chi-squared
Primary
Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities
Participants will answer questions about their participation in 26 daily activities, as well as their desire to participate in each of the 26 daily activities. This is a measure of those who indicated they wanted to increase their participation. 10 of the 26 activities and their outcome measures are listed below. Activity 1: Walking from one place to another outside of your home on a flat surface. Activity 2: Moving from one place to another using motorized transportation. Activity 3: Climbing two or more flights of stairs. Activity 4: Walking up a hill. Activity 5: Participating in regular exercise. Activity 6: Walking from one place to another in your home. Activity 7: Carrying light objects on a flat surface. Activity 8: Carrying heavy objects on a flat surface. Activity 9: Carrying-out low intensity physical activities
Time frame: Baseline
Population: Participants answered an online survey and their medical chart information was gathered to compare responses across disease severity. Of the 148 participants, 130 completed the online survey with spirometry \& exacerbation and mMRC for Group ABCD analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 6 | 3 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 4 | 142 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 1 | 108 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 3 | 114 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 9 | 30 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 8 | 99 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 5 | 117 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 2 | 17 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 10 | 90 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 7 | 19 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 1 | 83 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 3 | 101 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 10 | 71 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 2 | 25 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 9 | 28 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 4 | 107 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 6 | 0 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 7 | 15 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 8 | 86 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 5 | 87 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 10 | 5 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 8 | 11 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 2 | 5 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 4 | 24 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 7 | 5 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 9 | 5 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 5 | 22 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 3 | 24 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 6 | 0 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 1 | 8 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 3 | 27 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 4 | 41 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 6 | 0 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 2 | 3 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 5 | 22 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 10 | 17 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 7 | 3 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 8 | 22 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 1 | 27 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 9 | 3 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 8 | 28 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 10 | 30 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 7 | 3 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 1 | 30 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 3 | 22 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 9 | 3 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 2 | 3 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 5 | 32 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 4 | 39 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 6 | 3 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 1 | 43 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 2 | 6 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 4 | 38 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 6 | 0 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 8 | 38 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 3 | 41 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 5 | 41 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 7 | 8 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 9 | 19 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 10 | 38 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 3 | 12 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 5 | 8 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 6 | 0 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 1 | 8 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 9 | 8 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 8 | 7 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 2 | 15 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 10 | 0 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 7 | 4 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 4 | 19 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 7 | 6 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 4 | 44 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 5 | 44 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 6 | 0 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 10 | 24 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 3 | 30 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 8 | 27 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 2 | 2 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 9 | 8 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 1 | 38 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 2 | 0 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 4 | 0 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 9 | 7 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 7 | 0 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 3 | 21 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 5 | 7 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 8 | 14 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 10 | 14 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 1 | 7 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 6 | 0 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 9 | 5 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 4 | 44 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 8 | 38 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 2 | 8 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 7 | 5 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 6 | 0 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 1 | 30 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 5 | 28 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 10 | 33 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities | Activity 3 | 38 participants |
Comparison: Activity 1: Walking from one place to another outside of your home on a flat surfacep-value: 0.05Chi-squared
Comparison: Activity 2: Moving from one place to another using motorized transportationp-value: 0.87Chi-squared
Comparison: Activity 3: Climbing two or more flights of stairsp-value: 0.65Chi-squared
Comparison: Activity 4: Walking up a hillp-value: 0.35Chi-squared
Comparison: Activity 5: Participating in regular exercise requiring physical effort, to maintain or improve health or fitnessp-value: 0.03Chi-squared
Comparison: Activity 1: Walking from one place to another outside of your home on a flat surfacep-value: 0Chi-squared
Comparison: Activity 2: Moving from one place to another using motorized transportationp-value: 0.33Chi-squared
Comparison: Activity 3: Climbing two or more flights of stairsp-value: 0Chi-squared
Comparison: Activity 4: Walking up a hillp-value: 0.01Chi-squared
Comparison: Activity 5: Participating in regular exercise requiring physical effort, to maintain or improve health or fitnessp-value: 0.02Chi-squared
Secondary
COPD Assessment Test
This questionnaire measure the impact COPD is having on well being and daily life. The CAT is an eight-item semantic differential scale from 0 to 5, where 0 is no impact and 5 is extremely impactful. Items include: I never cough\| I cough all the time, I have no phlegm (mucus) in my chest at all \| My chest is completely full of phlegm (mucus), My chest does not feel tight at all \| My chest feels very tight, When I walk up a hill or one flight of stairs, I am not breathless \| When I walk up a hill or one flight of stairs, I am very breathless, I am not limited doing any activities at home\| I am very limited doing activities at home, I am confident leaving my home despite my lung condition\| I am not at all confident leaving my home because of my lung condition, I sleep soundly \| I don't sleep soundly because of my lung condition, I have lots of energy I have no energy at all. Participants' scores were totaled and a score of ≥ 10 indicated higher than normal burden of disease.
Time frame: Baseline
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Participation Differences by Individuals' Disease Severity | COPD Assessment Test | CAT ≥10 | 122 participants |
| Participation Differences by Individuals' Disease Severity | COPD Assessment Test | CAT <10 | 24 participants |
| Participation Differences by Individuals' Disease Severity | COPD Assessment Test | Data missing | 2 participants |
| Participation Differences by (GOLD) ABCD Classification | COPD Assessment Test | CAT <10 | 22 participants |
| Participation Differences by (GOLD) ABCD Classification | COPD Assessment Test | Data missing | 1 participants |
| Participation Differences by (GOLD) ABCD Classification | COPD Assessment Test | CAT ≥10 | 107 participants |
| Quartile 1 - Mild Airflow Obstruction | COPD Assessment Test | Data missing | 1 participants |
| Quartile 1 - Mild Airflow Obstruction | COPD Assessment Test | CAT <10 | 10 participants |
| Quartile 1 - Mild Airflow Obstruction | COPD Assessment Test | CAT ≥10 | 26 participants |
| Quartile 2 - Moderate Airflow Obstruction | COPD Assessment Test | CAT <10 | 5 participants |
| Quartile 2 - Moderate Airflow Obstruction | COPD Assessment Test | CAT ≥10 | 32 participants |
| Quartile 2 - Moderate Airflow Obstruction | COPD Assessment Test | Data missing | 0 participants |
| Quartile 3 - Severe Airflow Obstruction | COPD Assessment Test | CAT <10 | 6 participants |
| Quartile 3 - Severe Airflow Obstruction | COPD Assessment Test | Data missing | 1 participants |
| Quartile 3 - Severe Airflow Obstruction | COPD Assessment Test | CAT ≥10 | 30 participants |
| Quartile 4 - Very Severe Airflow Obstruction | COPD Assessment Test | Data missing | 0 participants |
| Quartile 4 - Very Severe Airflow Obstruction | COPD Assessment Test | CAT ≥10 | 34 participants |
| Quartile 4 - Very Severe Airflow Obstruction | COPD Assessment Test | CAT <10 | 3 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | Data missing | 0 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | CAT ≥10 | 18 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | CAT <10 | 8 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | CAT ≥10 | 44 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | CAT <10 | 6 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | Data missing | 0 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | CAT <10 | 5 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | CAT ≥10 | 9 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | Data missing | 0 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | Data missing | 1 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | CAT <10 | 3 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | COPD Assessment Test | CAT ≥10 | 36 participants |
p-value: 0.31ANOVA
Secondary
FEV1/FVC
Individuals FEV1-to-forced vital capacity (FVC) ratio
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Participation Differences by Individuals' Disease Severity | FEV1/FVC | 49.1 Measured ratio | Standard Deviation 11.8 |
| Participation Differences by (GOLD) ABCD Classification | FEV1/FVC | 49.0 Measured ratio | Standard Deviation 11.9 |
| Quartile 1 - Mild Airflow Obstruction | FEV1/FVC | 60.5 Measured ratio | Standard Deviation 8.5 |
| Quartile 2 - Moderate Airflow Obstruction | FEV1/FVC | 53.8 Measured ratio | Standard Deviation 8.5 |
| Quartile 3 - Severe Airflow Obstruction | FEV1/FVC | 44.1 Measured ratio | Standard Deviation 8.9 |
| Quartile 4 - Very Severe Airflow Obstruction | FEV1/FVC | 38.1 Measured ratio | Standard Deviation 7.9 |
| Group A - Breathlessness Burden and Exacerbation Risk | FEV1/FVC | 58.1 Measured ratio | Standard Deviation 7.3 |
| Group B - Breathlessness Burden and Exacerbation Risk | FEV1/FVC | 47.9 Measured ratio | Standard Deviation 11.2 |
| Group C - Breathlessness Burden and Exacerbation Risk | FEV1/FVC | 49.1 Measured ratio | Standard Deviation 12.8 |
| Group D - Breathlessness Burden and Exacerbation Risk | FEV1/FVC | 44.5 Measured ratio | Standard Deviation 12 |
p-value: 0ANOVA
Secondary
Forced Expiratory Volume in 1-sec (FEV1)
Individuals forced expiratory volume in 1-sec (FEV1) as assessed by spirometry
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Participation Differences by Individuals' Disease Severity | Forced Expiratory Volume in 1-sec (FEV1) | 49.6 percent predicted | Standard Deviation 23.2 |
| Participation Differences by (GOLD) ABCD Classification | Forced Expiratory Volume in 1-sec (FEV1) | 48.5 percent predicted | Standard Deviation 20.7 |
| Quartile 1 - Mild Airflow Obstruction | Forced Expiratory Volume in 1-sec (FEV1) | 79.0 percent predicted | Standard Deviation 21.5 |
| Quartile 2 - Moderate Airflow Obstruction | Forced Expiratory Volume in 1-sec (FEV1) | 55.6 percent predicted | Standard Deviation 5.5 |
| Quartile 3 - Severe Airflow Obstruction | Forced Expiratory Volume in 1-sec (FEV1) | 38.5 percent predicted | Standard Deviation 4.8 |
| Quartile 4 - Very Severe Airflow Obstruction | Forced Expiratory Volume in 1-sec (FEV1) | 25.2 percent predicted | Standard Deviation 4.5 |
| Group A - Breathlessness Burden and Exacerbation Risk | Forced Expiratory Volume in 1-sec (FEV1) | 66.0 percent predicted | Standard Deviation 20.2 |
| Group B - Breathlessness Burden and Exacerbation Risk | Forced Expiratory Volume in 1-sec (FEV1) | 47.1 percent predicted | Standard Deviation 17.9 |
| Group C - Breathlessness Burden and Exacerbation Risk | Forced Expiratory Volume in 1-sec (FEV1) | 50.8 percent predicted | Standard Deviation 20.3 |
| Group D - Breathlessness Burden and Exacerbation Risk | Forced Expiratory Volume in 1-sec (FEV1) | 37.8 percent predicted | Standard Deviation 17 |
p-value: 0Kruskal-Wallis
Secondary
Godin Leisure Time Physical Activity Questionnaire
Self-reported physical activity levels measured in length of bouts over the previous 7 days to determine physical activity frequency.
Time frame: Baseline
Population: Missing data n=8 for differences by individuals' disease severity and n=4 for differences by (GOLD) ABCD
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Participation Differences by Individuals' Disease Severity | Godin Leisure Time Physical Activity Questionnaire | 74.64 Total minutes of Moderate to Vigorous PA | Standard Deviation 138.59 |
| Participation Differences by (GOLD) ABCD Classification | Godin Leisure Time Physical Activity Questionnaire | 101.86 Total minutes of Moderate to Vigorous PA | Standard Deviation 194.49 |
| Quartile 1 - Mild Airflow Obstruction | Godin Leisure Time Physical Activity Questionnaire | 100.29 Total minutes of Moderate to Vigorous PA | Standard Deviation 170.08 |
| Quartile 2 - Moderate Airflow Obstruction | Godin Leisure Time Physical Activity Questionnaire | 117.06 Total minutes of Moderate to Vigorous PA | Standard Deviation 175.61 |
| Quartile 3 - Severe Airflow Obstruction | Godin Leisure Time Physical Activity Questionnaire | 42.78 Total minutes of Moderate to Vigorous PA | Standard Deviation 90.57 |
| Quartile 4 - Very Severe Airflow Obstruction | Godin Leisure Time Physical Activity Questionnaire | 40.06 Total minutes of Moderate to Vigorous PA | Standard Deviation 79.7 |
| Group A - Breathlessness Burden and Exacerbation Risk | Godin Leisure Time Physical Activity Questionnaire | 166.52 Total minutes of Moderate to Vigorous PA | Standard Deviation 204.52 |
| Group B - Breathlessness Burden and Exacerbation Risk | Godin Leisure Time Physical Activity Questionnaire | 33.38 Total minutes of Moderate to Vigorous PA | Standard Deviation 76.05 |
| Group C - Breathlessness Burden and Exacerbation Risk | Godin Leisure Time Physical Activity Questionnaire | 138.57 Total minutes of Moderate to Vigorous PA | Standard Deviation 149.35 |
| Group D - Breathlessness Burden and Exacerbation Risk | Godin Leisure Time Physical Activity Questionnaire | 39.10 Total minutes of Moderate to Vigorous PA | Standard Deviation 73.21 |
p-value: 0.04Kruskal-Wallis
Secondary
Modified Medical Research Council Questionnaire on Breathlessness
Self-reported intensity of activity related breathlessness as assessed by the modified Medical Research Council (mMRC) dyspnea scale (0-4). This questionnaire was used to measure participants' breathlessness burden using a single item scale from 0 to 4, where a score of 0-1 indicated mild breathlessness and 2-4 indicated increased breathlessness.
Time frame: Baseline
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Participation Differences by Individuals' Disease Severity | Modified Medical Research Council Questionnaire on Breathlessness | mMRC 0-1 | 45 participants |
| Participation Differences by Individuals' Disease Severity | Modified Medical Research Council Questionnaire on Breathlessness | mMRC ≥2 | 101 participants |
| Participation Differences by Individuals' Disease Severity | Modified Medical Research Council Questionnaire on Breathlessness | Data missing | 2 participants |
| Participation Differences by (GOLD) ABCD Classification | Modified Medical Research Council Questionnaire on Breathlessness | mMRC 0-1 | 40 participants |
| Participation Differences by (GOLD) ABCD Classification | Modified Medical Research Council Questionnaire on Breathlessness | mMRC ≥2 | 90 participants |
| Participation Differences by (GOLD) ABCD Classification | Modified Medical Research Council Questionnaire on Breathlessness | Data missing | 0 participants |
| Quartile 1 - Mild Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | mMRC ≥2 | 15 participants |
| Quartile 1 - Mild Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | Data missing | 2 participants |
| Quartile 1 - Mild Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | mMRC 0-1 | 20 participants |
| Quartile 2 - Moderate Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | mMRC ≥2 | 22 participants |
| Quartile 2 - Moderate Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | mMRC 0-1 | 15 participants |
| Quartile 2 - Moderate Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | Data missing | 0 participants |
| Quartile 3 - Severe Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | mMRC 0-1 | 7 participants |
| Quartile 3 - Severe Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | mMRC ≥2 | 30 participants |
| Quartile 3 - Severe Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | Data missing | 0 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | Data missing | 0 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | mMRC 0-1 | 3 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Modified Medical Research Council Questionnaire on Breathlessness | mMRC ≥2 | 34 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | mMRC 0-1 | 26 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | mMRC ≥2 | 0 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | Data missing | 0 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | Data missing | 0 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | mMRC 0-1 | 0 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | mMRC ≥2 | 50 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | Data missing | 0 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | mMRC ≥2 | 0 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | mMRC 0-1 | 14 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | mMRC 0-1 | 0 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | mMRC ≥2 | 40 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Modified Medical Research Council Questionnaire on Breathlessness | Data missing | 0 participants |
p-value: 0ANOVA
Secondary
Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months
An exacerbation was defined as a change in medication due to a COPD exacerbation (i.e., the prescription of prednisone or a medical action plan) as indicated in the medical chart or hospital admission due to a COPD exacerbation.
Time frame: baseline
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Participation Differences by Individuals' Disease Severity | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 0-1 exacerbations | 92 participants |
| Participation Differences by Individuals' Disease Severity | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 2+ or 1 exacerbations leading to hospital admission | 56 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 0-1 exacerbations | 76 participants |
| Participation Differences by (GOLD) ABCD Classification | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 2+ or 1 exacerbations leading to hospital admission | 54 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 0-1 exacerbations | 30 participants |
| Quartile 1 - Mild Airflow Obstruction | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 2+ or 1 exacerbations leading to hospital admission | 7 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 0-1 exacerbations | 27 participants |
| Quartile 2 - Moderate Airflow Obstruction | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 2+ or 1 exacerbations leading to hospital admission | 10 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 2+ or 1 exacerbations leading to hospital admission | 18 participants |
| Quartile 3 - Severe Airflow Obstruction | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 0-1 exacerbations | 19 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 2+ or 1 exacerbations leading to hospital admission | 21 participants |
| Quartile 4 - Very Severe Airflow Obstruction | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 0-1 exacerbations | 16 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 2+ or 1 exacerbations leading to hospital admission | 0 participants |
| Group A - Breathlessness Burden and Exacerbation Risk | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 0-1 exacerbations | 26 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 0-1 exacerbations | 50 participants |
| Group B - Breathlessness Burden and Exacerbation Risk | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 2+ or 1 exacerbations leading to hospital admission | 0 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 0-1 exacerbations | 0 participants |
| Group C - Breathlessness Burden and Exacerbation Risk | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 2+ or 1 exacerbations leading to hospital admission | 14 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 0-1 exacerbations | 0 participants |
| Group D - Breathlessness Burden and Exacerbation Risk | Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months | Number of participants with 2+ or 1 exacerbations leading to hospital admission | 40 participants |
Secondary
Satisfaction of Life Questionnaire
This 5 item questionnaire was used to measure participants' level of life satisfaction. The higher the score, the higher the sense of life satisfaction. A score from 5-9 indicated extremely dissatisfied, 10-14 is dissatisfied, 15-19 indicated slightly below average life satisfaction. 20-24 is the average score, 25-29 is a high score indicative of higher life satisfaction and a score between 30-35 is a very high score and represent very high life satisfaction.
Time frame: Baseline
Population: Missing data n=6 for differences by individuals' disease severity and n=6 for differences by (GOLD) ABCD
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Participation Differences by Individuals' Disease Severity | Satisfaction of Life Questionnaire | 18.62 total score on a scale | Standard Deviation 8.16 |
| Participation Differences by (GOLD) ABCD Classification | Satisfaction of Life Questionnaire | 18.38 total score on a scale | Standard Deviation 8.14 |
| Quartile 1 - Mild Airflow Obstruction | Satisfaction of Life Questionnaire | 22.51 total score on a scale | Standard Deviation 7.78 |
| Quartile 2 - Moderate Airflow Obstruction | Satisfaction of Life Questionnaire | 20.94 total score on a scale | Standard Deviation 7.68 |
| Quartile 3 - Severe Airflow Obstruction | Satisfaction of Life Questionnaire | 16.35 total score on a scale | Standard Deviation 7.23 |
| Quartile 4 - Very Severe Airflow Obstruction | Satisfaction of Life Questionnaire | 15.1 total score on a scale | Standard Deviation 7.87 |
| Group A - Breathlessness Burden and Exacerbation Risk | Satisfaction of Life Questionnaire | 22.50 total score on a scale | Standard Deviation 6.83 |
| Group B - Breathlessness Burden and Exacerbation Risk | Satisfaction of Life Questionnaire | 17.33 total score on a scale | Standard Deviation 8.1 |
| Group C - Breathlessness Burden and Exacerbation Risk | Satisfaction of Life Questionnaire | 21.67 total score on a scale | Standard Deviation 6.73 |
| Group D - Breathlessness Burden and Exacerbation Risk | Satisfaction of Life Questionnaire | 15.95 total score on a scale | Standard Deviation 8.26 |
p-value: 0ANOVA